New alliance will target major risk factor for Alzheimer's

Share this article:

A new collaboration will see four leading academic research laboratories working with AstraZeneca to study a major risk factor for Alzheimer's disease. Steven Paul, M.D., of Weill Cornell Medical College and AstraZeneca jointly announced the A5 Alliance. Collectively, the alliance will examine the apolipoprotein E4 genotype (ApoE). “We are convinced that ApoE represents a major piece of the Alzheimer's disease puzzle,” Paul noted. Additional members include David Holtzman, M.D. of Washington University in St. Louis, Peter Davies, Ph.D., of The Feinstein Institute for Medical Research and Cheryl Wellington, Ph.D., of the University of British Columbia.

Share this article:
close

Next Article in Products

More in Products

ACO white paper geared toward post-acute providers

A new white paper focuses on what kinds of services accountable care organizations should provide in the post-acute spectrum.

Accutech Security releases wander management system

Accutech Security releases wander management system

Accutech Security has released its new ResidentGuard LS 2400 wander management system, which can be used in senior living settings.

Sharps Compliance Corp. and MedReturn, LLC launch MedSafe

Sharps Compliance Corp. and MedReturn, LLC launch MedSafe

The Sharps Compliance Corp. and MedReturn LLC have created MedSafe, a system set up to dispose of unwanted and expired medications, including controlled substances.